Skip to content

Clinical Transformation Study of Guben Qushi Huayu Formula for Treatment of Mild-Moderate Ulcerative Colitis

Clinical Transformation Study of Guben Qushi Huayu Formula for Treatment of Mild-Moderate Ulcerative Colitis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900025640
Enrollment
Unknown
Registered
2019-09-03
Start date
2019-09-05
Completion date
Unknown
Last updated
2019-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative Colitis

Interventions

Sponsors

The Second Affiliated Hospital of Guangzhou University of TCM
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Cases that meet the clinical diagnosis and definitive diagnosis of Western diagnostic criteria; 2. Meets the criteria for ulcerative colitis in mild to moderate active periods; 3. Diagnostic criteria for spleen deficiency and dampness syndrome in line with expert consensus; 4. Signed informed consent, good compliance, and follow-up; 5. Outpatient or hospitalized patients aged 18 to 70 years; 6. Do not use drugs or other treatments that affect the evaluation of efficacy during treatment.

Exclusion criteria

Exclusion criteria: 1. Lactation, pregnant women, and patients intolerant to this drug; 2. Severe primary disease such as severe heart, lung, liver, kidney and hematopoietic system, mental patients; 3. Patients with serious complications such as local stenosis, toxic megacolon, intestinal obstruction, colon cancer, rectal cancer, intestinal perforation and anal disease; 4. Persons with disabilities prescribed by law (dumb, sputum, blindness, mental disorder, physical disability, mental retardation).

Design outcomes

Primary

MeasureTime frame
UC disease activity index;Inflammatory bowel disease quality of life questionnaire;intestinal mucosal scores;Disease remission rate;erythrocyte sedimentation rate and C-reactin protein;Single symptom efficacy;TCM syndrome effect;

Countries

China

Contacts

Public ContactHuang Shaogang

The Second Affiliated Hospital of Guangzhou University of TCM

huangshaogang@126.com+86 13926451320

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026